Preclinical Efficacy Testing for Stomach and Liver Cancers

Cancer Research and Treatment

Volumn 46, Issue 2, 2014, Pages 186-193

  Park, Jun Won ^a,b   Baek, Nam Suk ^a   Lee, Seok Cheol ^a   Oh, Su Jin ^a   Jang, Seok Hoon ^a   Kim, In Hoo ^a   Kim, Dae Yong ^b   Kim, Hark Kyun ^a  

^a National Cancer Center   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Hollow fiber assay; Liver neoplasms; Stomach neoplasms; Xenograft model antitumor assay

Indexed keywords

EW 7197; FLAVOPIRIDOL; ORGANIC COMPOUND; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSAY; CANCER REGRESSION; CONTROLLED STUDY; FEMALE; GASTRIC CANCER CELL LINE; HEPATOCELLULAR CARCINOMA CELL LINE; HOLLOW FIBER; HOLLOW FIBER ASSAY; HUMAN; HUMAN CELL; INOCULATION; MALE; MOUSE; NONHUMAN;

EID: 84900456945     PISSN: 15982998     EISSN: 20059256     Source Type: Journal    
DOI: 10.4143/crt.2014.46.2.186     Document Type: Article

References (19)

1. Phillips RM, Bibby MC, Double JA. A critical appraisal of the predictive value of in vitro chemosensitivity assays. J Natl Cancer Inst. 1990;82:1457-68.
2. Sharma SV, Haber DA, Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer. 2010;10:241-53.
3. Hollingshead MG, Alley MC, Camalier RF, Abbott BJ, Mayo JG, Malspeis L, et al. In vivo cultivation of tumor cells in hollow fibers. Life Sci. 1995;57:131-41.
4. Hall LA, Krauthauser CM, Wexler RS, Hollingshead MG, Slee AM, Kerr JS. The hollow fiber assay: continued characterization with novel approaches. Anticancer Res. 2000;20:903-11.
5. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer. 2001;84:1424-31.
6. Lee KH, Rhee KH. Correlative effect between in vivo hollow fiber assay and xenografts assay in drug screening. Cancer Res Treat. 2005;37:196-200.
7. Jung KW, Park S, Kong HJ, Won YJ, Lee JY, Park EC, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008. Cancer Res Treat. 2011;43:1-11.
8. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19:1893-907.
9. Kim SW, Kim SJ, Park SA, Kim MJ, Kim DK, Sheen YY. Antimetastasis effect of EW-7197, a novel ALK5 inhibitor in both breast cancer cells in vitro and mouse model in vivo. Cancer Res. 2012;72(8 Suppl 1):Abstr 1918.
10. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 1971;93:2325-7.
11. Rose WC. Taxol: a review of its preclinical in vivo antitumor activity. Anticancer Drugs. 1992;3:311-21.
12. Park JG, Frucht H, LaRocca RV, Bliss DP Jr, Kurita Y, Chen TR, et al. Characteristics of cell lines established from human gastric carcinoma. Cancer Res. 1990;50:2773-80.
13. Bar-Am I, Mor O, Yeger H, Shiloh Y, Avivi L. Detection of amplified DNA sequences in human tumor cell lines by fluorescence in situ hybridization. Genes Chromosomes Cancer. 1992;4:314-20.
14. Park JG, Yang HK, Kim WH, Chung JK, Kang MS, Lee JH, et al. Establishment and characterization of human gastric carcinoma cell lines. Int J Cancer. 1997;70:443-9.
15. Kim JH, Takahashi T, Chiba I, Park JG, Birrer MJ, Roh JK, et al. Occurrence of p53 gene abnormalities in gastric carcinoma tumors and cell lines. J Natl Cancer Inst. 1991;83:938-43.
16. Heffelfinger SC, Hawkins HH, Barrish J, Taylor L, Darlington GJ. SK HEP-1: a human cell line of endothelial origin. In Vitro Cell Dev Biol. 1992;28A:136-42.
17. Sassa S, Sugita O, Galbraith RA, Kappas A. Drug metabolism by the human hepatoma cell, Hep G2. Biochem Biophys Res Commun. 1987;143:52-7.
18. Mersch-Sundermann V, Knasmuller S, Wu XJ, Darroudi F, Kassie F. Use of a human-derived liver cell line for the detection of cytoprotective, antigenotoxic and cogenotoxic agents. Toxicology. 2004;198:329-40.
19. Drees M, Dengler WA, Roth T, Labonte H, Mayo J, Malspeis L, et al. Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin Cancer Res. 1997;3:273-9.